5 research outputs found

    Chronic myeloid leukaemia presenting with priapism as the only symptom: A case report and review of literature

    Get PDF
    Objective: There have been few reports of priapism as complications of various haematological malignancies. Delays in establishing the cause and late institution of appropriate intervention in patients suffering from priapism could result in long-term complications, especially erectile dysfunction. We present here a case of chronic myeloid leukaemia (CML) in a 30 year old male who presented with priapism as the only symptom. Apart from presenting this as a rare case report, it also emphasizes the need for early full blood count in patients presenting with priapism.Methods: The case note of the patient, as well as all available literature on the subject were reviewed.Results: The 30 year old man who presented with a 9 (nine) day history of persistent painful non-sexually related penile erection was found to have chronic myeloid leukaemia (CML) following peripheral and bone marrow aspiration studies. He however had a delay in referral and diagnosis of his primary condition and eventually had erectile dysfunction. The priapism responded well to surgical intervention and use of cyto-reductive therapy. The erectile dysfunction could have been averted if complete blood count and, or peripheral blood film were carried out at the time of first presentationConclusion: Priapism due to hyperviscosity can be the first presentation in patients with Chronic Myeloid Leukaemia, and CML should therefore always be considered in a patient with priapism. High Index of Suspicion, as well as early full blood count and peripheral blood/Bone marrow examination among patients presenting with priapism will facilitate prompt and correct diagnosis, and reduce, if not prevent erectile dysfunction and other severe complications that may arise from priapism.Keywords: Priapism, Chronic myeloid leukaemia, erectile dysfunctio

    The effect of pyridoxine supplementation on quality of life of patients with chronic lymphocytic leukaemia

    Get PDF
    Objective: Pyridoxine, is essential in the metabolism of many classes of food, we aimed at determining the effect of its supplementation on the quality of life (QoL) of patients with chronic lymphocytic leukaemia (CLL).Methods: This study compared the (QoL) and haematological parameters of CLL patients before and after the administration of pyridoxine. Data obtained were analyzed using SPSS version 19.Results: There was improvement in the QoL of the patients after pyridoxine supplementation; Majority of the parameters that make up the physical functional scales was significantly higher after pyridoxine supplementation. There were also significant improvements in insomnia, appetite loss and constipation after pyridoxine supplementation.Conclusion: Pyridoxine supplementation in patients with CLL marginally improved quality of life.Keywords: Pyridoxine, Supplementation, Quality of life, Leukaemia, CL

    Safety of hospital discharge before return of bowel function after elective colorectal surgery

    No full text
    © 2020 BJS Society Ltd Published by John Wiley & Sons LtdBackground: Ileus is common after colorectal surgery and is associated with an increased risk of postoperative complications. Identifying features of normal bowel recovery and the appropriateness for hospital discharge is challenging. This study explored the safety of hospital discharge before the return of bowel function. Methods: A prospective, multicentre cohort study was undertaken across an international collaborative network. Adult patients undergoing elective colorectal resection between January and April 2018 were included. The main outcome of interest was readmission to hospital within 30 days of surgery. The impact of discharge timing according to the return of bowel function was explored using multivariable regression analysis. Other outcomes were postoperative complications within 30 days of surgery, measured using the Clavien–Dindo classification system. Results: A total of 3288 patients were included in the analysis, of whom 301 (9·2 per cent) were discharged before the return of bowel function. The median duration of hospital stay for patients discharged before and after return of bowel function was 5 (i.q.r. 4–7) and 7 (6–8) days respectively (P < 0·001). There were no significant differences in rates of readmission between these groups (6·6 versus 8·0 per cent; P = 0·499), and this remained the case after multivariable adjustment for baseline differences (odds ratio 0·90, 95 per cent c.i. 0·55 to 1·46; P = 0·659). Rates of postoperative complications were also similar in those discharged before versus after return of bowel function (minor: 34·7 versus 39·5 per cent; major 3·3 versus 3·4 per cent; P = 0·110). Conclusion: Discharge before return of bowel function after elective colorectal surgery appears to be safe in appropriately selected patients

    Safety of hospital discharge before return of bowel function after elective colorectal surgery

    No full text
    Background: Ileus is common after colorectal surgery and is associated with an increased risk of postoperative complications. Identifying features of normal bowel recovery and the appropriateness for hospital discharge is challenging. This study explored the safety of hospital discharge before the return of bowel function. Methods: A prospective, multicentre cohort study was undertaken across an international collaborative network. Adult patients undergoing elective colorectal resection between January and April 2018 were included. The main outcome of interest was readmission to hospital within 30 days of surgery. The impact of discharge timing according to the return of bowel function was explored using multivariable regression analysis. Other outcomes were postoperative complications within 30 days of surgery, measured using the Clavien\u2013Dindo classification system. Results: A total of 3288 patients were included in the analysis, of whom 301 (9\ub72 per cent) were discharged before the return of bowel function. The median duration of hospital stay for patients discharged before and after return of bowel function was 5 (i.q.r. 4\u20137) and 7 (6\u20138) days respectively (P &lt; 0\ub7001). There were no significant differences in rates of readmission between these groups (6\ub76 versus 8\ub70 per cent; P = 0\ub7499), and this remained the case after multivariable adjustment for baseline differences (odds ratio 0\ub790, 95 per cent c.i. 0\ub755 to 1\ub746; P = 0\ub7659). Rates of postoperative complications were also similar in those discharged before versus after return of bowel function (minor: 34\ub77 versus 39\ub75 per cent; major 3\ub73 versus 3\ub74 per cent; P = 0\ub7110). Conclusion: Discharge before return of bowel function after elective colorectal surgery appears to be safe in appropriately selected patients

    Safety and efficacy of non-steroidal anti-inflammatory drugs to reduce ileus after colorectal surgery

    No full text
    Background: Ileus is common after elective colorectal surgery, and is associated with increased adverse events and prolonged hospital stay. The aim was to assess the role of non-steroidal anti-inflammatory drugs (NSAIDs) for reducing ileus after surgery. Methods: A prospective multicentre cohort study was delivered by an international, student- and trainee-led collaborative group. Adult patients undergoing elective colorectal resection between January and April 2018 were included. The primary outcome was time to gastrointestinal recovery, measured using a composite measure of bowel function and tolerance to oral intake. The impact of NSAIDs was explored using Cox regression analyses, including the results of a centre-specific survey of compliance to enhanced recovery principles. Secondary safety outcomes included anastomotic leak rate and acute kidney injury. Results: A total of 4164 patients were included, with a median age of 68 (i.q.r. 57\u201375) years (54\ub79 per cent men). Some 1153 (27\ub77 per cent) received NSAIDs on postoperative days 1\u20133, of whom 1061 (92\ub70 per cent) received non-selective cyclo-oxygenase inhibitors. After adjustment for baseline differences, the mean time to gastrointestinal recovery did not differ significantly between patients who received NSAIDs and those who did not (4\ub76 versus 4\ub78 days; hazard ratio 1\ub704, 95 per cent c.i. 0\ub796 to 1\ub712; P = 0\ub7360). There were no significant differences in anastomotic leak rate (5\ub74 versus 4\ub76 per cent; P = 0\ub7349) or acute kidney injury (14\ub73 versus 13\ub78 per cent; P = 0\ub7666) between the groups. Significantly fewer patients receiving NSAIDs required strong opioid analgesia (35\ub73 versus 56\ub77 per cent; P &lt; 0\ub7001). Conclusion: NSAIDs did not reduce the time for gastrointestinal recovery after colorectal surgery, but they were safe and associated with reduced postoperative opioid requirement
    corecore